CalliSpheres载药微球肝动脉栓塞治疗大肝癌的临床评价邱忠华，张伟伟，乔元岗，刘现闯济宁医学院附属医院介入治疗科山东济宁272000【摘要】目的探讨CalliSpheres载药微球经肝动脉栓塞治疗不可切除大肝癌的近期疗效及安全性。方法选取Cal-liSpheres载药微球肝动脉栓塞治疗的24例不可切除大肝癌患者(病灶直径大于5．0cm)的临床资料，采用mＲESET评价标准，评价临床治疗效果。结果24例患者成功进行了经肝动脉载药微球栓塞术，术前及术后1月ALT、ALB、TBIL、CＲE、WBC、PLT比较，差异无统计学意义(均P＞0．05);依据mＲESET标准，术后1、3、6个月的疾病缓解率OＲＲ(CＲ+PＲ)分别为83．33%、79．17%、75．00%;疾病控制率DCＲ(CＲ+PＲ+SD)分别为95．83%、95．83%、83．33%。所有患者未出现肝衰竭、肝脓肿及消化道出血等严重并发症。结论CalliSpheres载药微球肝动脉栓塞治疗不可切除大肝癌近期临床效果较好，安全可行，严重不良反应少，值得在临床进一步推广应用。【关键词】大肝癌;载药微球;肝动脉化疗栓塞;介入性，放射学中图分类号:Ｒ735．7;Ｒ815文献标识码:A文章编号:1006-9011(2023)04-0577-05ClinicalevaluationoftranscatheterhepaticarteryembolizationusingCalliSpheresdrug-loadedmicrospheresinthetreat-mentoflargelivercancerQIUZhonghua，ZHANGWeiwei，QIAOYuangang，LIUXianchuangDepartmentofInterventionalTherapy，AffiliatedHospitalofJiningMedicalUniversity，Jining272000，China【Abstract】ObjectiveToinvestigatetheshort-termefficacyandsafetyoftranscatheterhepaticarteryembolizationusingCalli-Spheresmicrospheresinthetreatmentofunresectablelargelivercancer．Methods24patientswithunresectablelargelivercanc-er(≥5cm)whounderwenttranscatheterhepaticarteryembolizationusingCalliSpheresmicrosphereswereperformed．AndthetumorresponsewasevaluatedaccordingtothemodifiedＲesponseEvaluationCriteriainSolidTumors(mＲESET)．ＲesultsTherewasnosignificantstatisticaldifferenceinALT，ALB，TBIL，CＲE，WBCandPLTindexesbeforeoperationandonemonthafteroperation．AccordingtomＲESET，theobjectiveresponserate(OＲＲ)was83．33%，79．17%and75．00%at1，3and6monthsafteroperation．Thediseasecontrolrates(DCＲ)were95．83%，95．83%and83．33%，respectively．Therewerenoma-jorcomplicationssuchaslive...
